hcvns3

HCV-IN-3 is a hepatitis C virus (HCV) NS3/4a protein inhibitor with an IC50 of 20 μM and a Kd of 29 μM.

Sovaprevir is a non-structural 3 (NS3) protease inhibitor with antiviral activity for the treatment of HCV infection.

4-Phenoxybenzylamine inhibits the function of the NS3 protein by stabilizing an inactive conformation, with an IC50 of approximately 500 μM against HCV NS3/4a.

BI-1230 is a potent inhibitor of HCV NS3 protease, exhibiting efficacy in the low nanomolar range, and notably suppresses viral replication. This compound demonstrates high selectivity, distinguishing effectively between other serine/cysteine proteases. Additionally, BI-1230 exhibits favorable pharmacokinetic (PK) properties[1].

Paritaprevir free base (ABT-450) is an orally bioavailable, synthetic acylsulfonamide inhibitor of the hepatitis C virus (HCV) protease complex comprised of non-structural protein 3 and 4A (NS3/NS4A), with potential activity against HCV genotype 1. Upon administration, paritaprevir reversibly binds to the active center and binding site of the HCV NS3/NS4A protease and prevents NS3/NS4A protease-mediated polyprotein maturation. This disrupts both the processing of viral proteins and the formation of the viral replication complex, which inhibits viral replication in HCV genotype 1-infected host cells.

HZ-1157 (DHFR-inhibitor) is a hepatitis C virus (HCV) inhibitor with inhibitory activities toward HCV NS3/4A protease.

Asunaprevir (BMS-650032) is an effective hepatitis C virus (HCV) NS3 protease inhibitor.

Grazoprevir (MK-5172) is a nitrogenous macrocyclic compound used as an inhibitor of the hepatitis C virus NS3/4A protease. Grazoprevir is commonly combined with elbasvir for treating chronic HCV genotype 1 or 4 infections in adults.

Simeprevir (TMC435) is a potent HCV NS3/4A protease inhibitor, and inhibits HCV replication with EC50 of 8 nM.

Boceprevir (SCH 503034) is a novel, potent, highly selective, orally bioavailable HCV NS3 protease inhibitor with Ki of 14 nM in both enzyme assay and EC90 of 350 nM in cell-based replicon assay.

Glecaprevir (ABT-493) is a small-molecule inhibitor that functions as an HCV NS3/4A protease inhibitor (IC50=3.5–11.3 nM) and also inhibits SARS-CoV-2 3CLpro (IC50=4.09 μM). It possesses oral bioavailability and antiviral activity, and is used for the treatment of hepatitis C as well as potential anti-coronavirus research.

Danoprevir (RG7227) is a peptidomimetic inhibitor of the NS3/4A protease(IC50=0.2-3.5 nM) of hepatitis C virus (HCV).

Telaprevir (Incivek) (VX-950) is an effective inhibitor of HCV NS3-4A serine protease (IC50: 0.35 μM).

Hepatitis C Virus S5A/5B, a synthetic peptide substrate, replicates the NS5A/5B junction of the nonstructural protein (NS), serving as the substrate for examining HCV NS3 protease activity [1].

Ac-DEMEEC-OH is a competitive inhibitor of the HCV NS3 protease with a Ki of 0.6 µM.